Assessment of Blood Tumor Mutational Burden as a Biomarker for Immunotherapy in NSCLC With Use of a Cancer Gene Panel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
JAMA Oncol 2019 Feb 28;[EPub Ahead of Print], Z Wang, J Duan, S Cai, M Han, H Dong, J Zhao, B Zhu, S Wang, M Zhuo, J Sun, Q Wang, H Bai, J Han, Y Tian, J Lu, T Xu, X Zhao, G Wang, X Cao, F Li, D Wang, Y Chen, Y Bai, J Zhao, Z Zhao, Y Zhang, L Xiong, J He, S Gao, J WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.